![The Development of CAR-T Cells Targeted by B7-H3 in Immunotherapy of Pancreatic Cancer: a Descriptive Research](https://founder-rc-product.oss-cn-zhangjiakou.aliyuncs.com/drawImage/202311/29/10/4365061517432248-a007-4b2b-90fa-b52e49ccb589_m.jpg?OSSAccessKeyId=LTAI3gp3WuRqpN5T&Signature=RjZbtik7g18%2FiLSF0wGZ%2B53ioVY%3D&response-content-type=image%2Fjpeg)
Volume 4, Issue 1
The Development of CAR-T Cells Targeted by B7-H3 in Immunotherapy of Pancreatic Cancer: a Descriptive Research
- Vol. 4, Issue 1, Pages: 43-47(2023)
DOI:10.47297/taposatWSP2633-456907.20230401
Full txt
Volume 4, Issue 1
School of Pharmacy of Xinhua College, Sun Yat-sen University,Guangdong,Guangzhou,P.R. China,510520
Full txt
Jiawei Lyu. (2023). The Development of CAR-T Cells Targeted by B7-H3 in Immunotherapy of Pancreatic Cancer: a Descriptive Research. Theory and Practice of Science and Technology, 4(1), 43-47.
Jiawei Lyu. (2023). The Development of CAR-T Cells Targeted by B7-H3 in Immunotherapy of Pancreatic Cancer: a Descriptive Research. Theory and Practice of Science and Technology, 4(1), 43-47. DOI: 10.47297/taposatWSP2633-456907.20230401.
Pancreatic cancer
as a common malignant disease in the digestive tract
has a very poor prognosis. Most patients are in the advanced stage when the disease is diagnosed
and a 5-year survival rate is less than 10%. Only 20 percent of diagnosed pancreatic cancer patients qualify for surgical treatment. The precise treatment of pancreatic cancer is still in the preliminary stage of exploration. In recent studies
a new breakthrough in CAR-T therapy for pancreatic cancer has been made
and CAR-T cells carrying the B7-H3 antibody have become the focal point of study. This paper reviews the advances in Pancreatic Cancer Therapy by B7-H3 CAR-T and analyses the problems in CAR-T therapy
aimed to help improve the safety coefficient of immunotherapy
and the future of targeted treatment of B7-H3 CAR-T in the pancreatic tumour was anticipated.
B7-H3CAR-Tpancreatic cancerimmunotherapy
Newick, K., Obrien, S., Moon, E., et al. (2017) .CAR-T Cell Therapy for Solid Tumors. Annual Review of Medicine, 68(1): 139-52.[2] Zhao, J., Lin, Q., Song, Y., et al. (2018) .Universal CARs, Universal T Cells, and Universal CAR-T Cells. Hematol Oncol, 11(1):132. [3] Barros, L.R.C. (2021). In Search of an Ideal CAR-T Cell Antigen Target. Crit Rev Immunol, 41(1):69-76. [4] Rodriguez-Garcia, A., Lynn, R.C., Poussin, M., et al. (2021). CAR-T Cell-mediated Depletion of Immunosuppressive Tumor-associated Macrophages Promotes Endogenous Antitumor Immunity and Augments Adoptive Immunotherapy. Nat Commun, 12(1):877.[5] Mehrabadi, A.Z., Ranjbar, R., Farzanehpour, M., et al. (2022). Therapeutic Potential of CAR-T Cell in Malignancies: A Scoping Review. Biomed Pharmacother, 146:112512. [6] Guo, F., Cui, J. (2021). Current Challenges and Optimization Strategies of CAR-T Cell Therapy for Solid Tumors. Chin J. Cancer Clinic, 49(12):617-21.[7] Chen, X. (2009) . Expression and Clinical Significance of Costimulatory Molecules B7-H1, B7-H3 and B7-H4 in Human Pancreatic Cancer. Soochow: Soochow University Press.[8] Xu, H., Chen, X., Tao, M., et al. (2016) . B7-H3 and B7-H4 Are Independent Predictors of a Poor Prognosis in Patients with Pancreatic Cancer. Oncology Letters, 11(3).[9] Zhao, X., Li, D., Zhu, X., et al. (2013). B7-H3 Over-expression in Pancreatic Cancer Promotes Tumor Progression. Int J Mol Med, 31(2):283-91.[10]Zhao X. (2013). The Role and Mechanism of a Novel Costimulatory Molecule B7-H3 in the Malignant Progression of Pancreatic Cancer. Thesis of Soochow University, 8: 132.[11]Du, H., Hirabayashi, K., Ahn, S., et al. (2019). Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer Cell, 35(2):221-37.[12]Nebbia, M., Sharazad, A., Deshpande, V., et al. (2022). Serum B7-H3 as a Novel Prognostic Biomarker for Patients with Pancreatic Adenocarcinoma. HPB, 24(S1).[13]Xu J, Huang B, Xiong P, et al..(2006). Soluble Mouse B7-H3 Down-regulates Dendritic Cell Stimulatory Capacity to Allogenic T Cell Proliferation and Production of IL-2 and IFN-gamma. Cell Mol Immunol. Jun; 3(3):235-40. [14]Zhao, X. (2013) .The Role and Mechanism of a Novel Costimulatory Molecule B7-H3 in the Malignant Progression of Pancreatic Cancer. Soochow University Press, Soochow.[15]Si, K., Xu, H., Ye, Z., et al. (2022). Antitumor Response of Anti-B7-H3 CAR-T Cells with Humanized scFv in Solid Tumors. Wuhan University Journal of Natural Sciences, 27(02):177-84.[16]Johnson, L., Lee, D., Eacret, J., et al. (2021) .The Immunostimulatory RNA RN7SL1 Enables CAR-T Cells to Enhance Autonomous and Endogenous Immune Function. Cell, 184(19):4981-95.
Related Articles
Related Author
Related Institution